BioNTech: pandemic preparedness contract awarded by the German Federal Ministry of Health – Form 6-K


BioNTech wins pandemic preparedness contract from the German Federal Ministry of Health

Mainz, Germany, April 8, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced that it was one of the German companies to be awarded a pandemic preparedness contract by the Federal Republic of Germany . The framework agreement targets pandemic preparedness, including the manufacture and supply of mRNA vaccines in emergency situations in Germany.

“There is growing evidence that viral pandemics will continue to pose a public health challenge for years to come. This contract with the German government will ensure a significant supply of vaccine doses to address potential public health threats by 2027,” said Sean Marett, Chief Commercial Officer and Chief Commercial Officer at BioNTech. “We are proud to be able to be a long-term partner for Germany and remain committed to our continued investment in research and development aimed at bringing new infectious disease vaccine candidates to people. and adapting our COVID-19 vaccine to address potential new and emerging variants.”

Under the Readiness Agreement, BioNTech will reserve and maintain manufacturing capabilities to produce at least 80 million doses of mRNA vaccine per year. The contract has an initial term of five years.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company operates a wide range of computational discovery and therapeutic drug platforms for the rapid development of new biopharmaceuticals. Its broad pipeline of oncology product candidates includes individualized, ready-to-use mRNA therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immunomodulators, targeted cancer antibodies and small molecules. . Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing several mRNA vaccine candidates for a range of infectious diseases alongside its diverse pipeline in oncology. BioNTech has established a wide range of relationships with several global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit

BioNTech Forward-Looking Statements

This press release contains “forward-looking statements” by BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, but are not limited to, statements regarding: BioNTech’s efforts to combat the COVID-19; the collaboration between BioNTech and Pfizer, including the COVID-19 vaccine development program and COMIRNATY (COVID-19 vaccine, mRNA) (BNT162b2) (including the potential for an Omicron-specific COVID-19 vaccine candidate or to another specific variant and qualitative assessments of available data, potential benefits, expectations regarding clinical trials, expected timing of regulatory submissions, regulatory approvals or clearances and anticipated manufacturing, distribution and supply); the duration and extent of the COVID-19 pandemic; the ability of BNT162b2 to prevent COVID-19 caused by emerging viral variants; BioNTech’s pipeline of infectious disease product candidates and the potential for such product candidates to obtain regulatory approval; and uncertainties

regarding the impact of COVID-19 on BioNTech’s trials, business activities and general operations. All forward-looking statements contained in this press release are based on BioNTech’s current expectations and beliefs regarding future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially. and adversely from those set forth or implied by such forward-looking statements.

For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the SEC on March 30, 2022, which is available on the SEC’s website at All information contained in this press release is as of the date of publication, and BioNTech undertakes no obligation to update this information except as required by law.



Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513

[email protected]

Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

[email protected]


Comments are closed.